$MXCT up 31% 🚀 🔹 MaxCyte ripping after Q1 2026 results and reaffirmed full-year guidance 📈 🔹 Company reported $9.7M in Q1 revenue, including $3.4M from Stra

$MXCT up 31% 🚀 🔹 MaxCyte ripping after Q1 2026 results and reaffirmed full-year guidance 📈 🔹 Company reported $9.7M in Q1 revenue, including $3.4M from Strategic Platform License programs 🔥 🔹 FY26 revenue outlook held at $30M–$32M, giving traders confidence in the turnaround setup 💥 🔹 MaxCyt…